Cambridge 'cannabis' firm wins £20.6m Novartis deal
Cambridge 'cannabis' firm wins £20.6m Novartis deal
Novartis will commercialise GW's Sativex – the world's first prescription medicine derived from cannabis – in certain key territories. They include Australasia, Asia (excluding Japan, China and Hong Kong), the Middle East (excluding Israel/Palestine) ...